Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04944940
Other study ID # 10000428
Secondary ID 000428-N
Status Recruiting
Phase
First received
Last updated
Start date October 25, 2021
Est. completion date February 28, 2027

Study information

Verified date April 5, 2024
Source National Institutes of Health Clinical Center (CC)
Contact Angela Kokkinis, R.N.
Phone (301) 451-8146
Email akokkinis@mail.cc.nih.gov
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: SBMA is an inherited chronic disease. It affects males in mid to late adulthood. It causes slowly progressive weakness of muscles and hand tremors. Researchers want to learn more about the effects of SBMA. Objective: To identify measurements that change over time in SBMA, including tests of muscle strength and function, as well as measurements of muscle and fat size. Eligibility: Men over the age of 18 both with and without a history of SBMA. Design: Participants will have a medical history, physical exam, and blood and urine tests. They will have neuromuscular ultrasound. They will have a lumbar puncture to obtain spinal fluid. For this, a needle will be inserted into the spinal canal in the lower back. Participants will have muscle strength and function tests. These tests may include pushing, pulling, rising from a chair and sitting back down, and/or walking. During these tests, they may wear an accelerometer (activity tracker) on their wrist. Participants will get an activity tracker to wear on their wrist for 10 days at home every 3 months. Participants with SBMA will also have lower limb magnetic resonance imaging (MRI) and optional whole-body MRI. They will have lung function tests. They will have speech and swallow tests. They will complete questionnaires. They may have optional body scans to measure bone density and lean body mass. They may have optional muscle biopsies. For biopsies, a needle will be used to take a small piece of muscle from the leg. Participants with SBMA will have 5 study visits over 2 years (every 6 months). Participants without SBMA will have 1 study visit.


Description:

Study Description: Spinal and bulbar muscular atrophy (SBMA) is an inherited form of motor neuron disease caused by a CAG-repeat expansion in the androgen receptor gene on the X chromosome for which there is no treatment currently. Biomarkers will be collected from participants with SBMA during this study to understand the natural history and progression of the disease. Objectives: The main objective of this study is to develop clinical, molecular and imaging outcome parameters that correlate with disease progression and severity and that predict clinical decline. These biomarkers and outcome measures can serve as potential tools for the evaluation of efficacy in future therapeutic studies in SBMA. Endpoints: The studies performed under this protocol are exploratory. However, the following measures may be used to characterize baseline status and disease progression over the course of the study: Muscle strength by manual and quantitative myometry Distance traveled in meters on the 6-minute walk test Activity levels as measured by an accelerometer Global disability measured by the SBMAFRS questionnaire Fatigue as measured by the Fatigue Severity Scale Breathing function measured by pulmonary function test Swallow and speech function measured by questionnaires, tongue muscle strength, digital audio recordings for analysis of voice and speech, and barium swallow Skeletal muscle MRI measurement of muscle volume and fat fraction Whole body MRI measurement of body muscle fat fraction, muscle fat infiltration, and liver. Skeletal muscle ultrasound measurement of muscle thickness, echogenicity and elasticity Nerve ultrasound measurement of nerve cross sectional area and anterior posterior diameter Laboratory studies from blood, serum, urine, and CSF Muscle biopsy assessment of androgen receptor levels and function Study Population: There will be a total of up to 70 male participants in this study. The target number of completers is 25 male participants with genetically confirmed SBMA and 25 healthy male participants who are age (plus or minus 5 years) and sex matched to the SBMA participants. Description of Sites/Facilities Enrolling Participants: NIH Clinical Center Study Duration: 48 months for data collection and analysis Participant Duration: SBMA participants will be seen for a baseline visit followed by a visit every six months for a total of 5 visits (about 29 months). Healthy volunteers will have a single visit.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date February 28, 2027
Est. primary completion date December 30, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 120 Years
Eligibility - INCLUSION CRITERIA: Some restrictions are placed on participation in the study because we aim to identify disease biomarkers specific to those with early t intermediate stages of disease who would be potential candidates for future therapeutic studies. In order to be eligible to participate in the SBMA cohort, an individual must meet all of the following criteria: - Stated willingness to comply with all study procedures and availability for the duration of the study - Male, above the age of 18 years - Genetically confirmed SBMA - Ability of subject to understand and the willingness to sign a written informed consent document - Ability of subject to travel to the NIH Clinical Center. Note: an SBMA patient who meets both of the additional following criteria will be offered an optional whole body MRI at subsequent follow-up visits: - Spinal bulbar muscular atrophy functional rating of < 50 (and > 35). - On initial whole body MRI, subject has evidence of muscle fat replacement such that the total volume of disease affected muscles (i.e., muscles with at least 10% muscle fat infiltration and no more than 50% muscle fat fraction) is at least: - 500ml if only 1 muscle is eligible or - 250ml if more than one muscle meets the criteria In order to be eligible to participate in this study in the Healthy Control cohort, an individual must meet all of the following criteria: - Stated willingness to comply with all study procedures and availability to travel to the NIH for the duration of the study - Male, above the age of 18 years - No history of SBMA or other neuromuscular disorder - No history of facial palsy - Ability of subject to understand and the willingness to sign a written informed consent document - Ability of subject to travel to the NIH Clinical Center. EXCLUSION CRITERIA: SBMA is a disease that affects males and manifests in adulthood. Thus, woman and children are not included in this study. This study will not include individuals who lack consent capacity. An SBMA patient who meets any of the following criteria will be excluded from participation in this study: - Contraindications to MRI such as a contraindicated non-removable metal device (i.e., pacemaker, defibrillator, insulin pump, metal clips, non-removable jewelry) or claustrophobia. - Non ambulatory - PT/PTT values that are prolonged greater than or equal to 3 seconds from the upper limit of normal (including treatment with oral and parenteral anticoagulants) - INR greater than or equal to 1.5, thrombocytopenia (<70,000), or abnormal bleeding time or platelet dysfunction - History of a bleeding disorder - Use of anticoagulants - Use of androgen reducing agents within the past two years Note: An SBMA patient who meets any of the following criteria will be excluded from the lumbar puncture procedure: - PT/PTT values that are prolonged greater than or equal to 3 seconds from the upper limit of normal (including treatment with oral and parenteral anticoagulants) - INR greater than or equal to 1.5, thrombocytopenia (less than 70,000), or abnormal bleeding time or platelet dysfunction - History of a bleeding disorder - Use of anticoagulants Note: An SBMA patient who meets any of the following criteria will be excluded from the muscle biopsy procedure: - Advanced wasting of tibialis anterior that precludes needle muscle biopsy (in order to ensure that a sample taken would be of muscle and not just fat and fascia) - Use of aspirin or non-steroidal anti-inflammatory agents 3 days prior to the procedure Note: An SBMA patient who meets any of the following criteria will be excluded from the whole body MRI: - Patient has a history of prior treatment with androgen reducing agents including LHRH agonists or antagonists, androgen receptor antagonists and selective androgen receptor modifiers. - Patient is unable to complete the study assessments of QMT or timed walk tests. - Patient anticipates making major lifestyle changes during the observation period relating to diet and exercise. A Healthy Control participant who meets any of the following criteria will be excluded from the study: - PT/PTT values that are prolonged greater than or equal to 3 seconds from the upper limit of normal (including treatment with oral and parenteral anticoagulants) - INR greater than or equal to 1.5, thrombocytopenia (less than 70,000), or abnormal bleeding time or platelet dysfunction - History of a bleeding disorder - Use of anticoagulants

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States National Institutes of Health Clinical Center Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States, 

References & Publications (2)

Atsuta N, Watanabe H, Ito M, Banno H, Suzuki K, Katsuno M, Tanaka F, Tamakoshi A, Sobue G. Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain. 2006 Jun;129(Pt 6):1446-55. doi: 10.1093/brain/awl096. Epub 2006 Apr 18. — View Citation

Rhodes LE, Freeman BK, Auh S, Kokkinis AD, La Pean A, Chen C, Lehky TJ, Shrader JA, Levy EW, Harris-Love M, Di Prospero NA, Fischbeck KH. Clinical features of spinal and bulbar muscular atrophy. Brain. 2009 Dec;132(Pt 12):3242-51. doi: 10.1093/brain/awp258. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Disease progression as measured by clinical and molecular tests Clinical measurements include MRI, DEXA, physical function, swallow, and pulmonary testing. Molecular measurements include serum and plasma biomarkers, muscle analysis, and urine testing. Baseline to visits every 6 months to 2 years
See also
  Status Clinical Trial Phase
Terminated NCT04579666 - MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Completed NCT03706391 - Study of ALS Reversals 4: LifeTime Exposures
Active, not recruiting NCT03067857 - Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease Phase 1/Phase 2
Completed NCT02464748 - Telehealth in Motor Neurone Disease N/A
Completed NCT00956488 - Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis Phase 1/Phase 2
Terminated NCT00537446 - Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis N/A
Recruiting NCT03362658 - Novel MRI Biomarkers for Monitoring Disease Progression in ALS
Completed NCT00714636 - Cerebrospinal Fluid Repository N/A
Completed NCT00071435 - Brain Function in Primary Lateral Sclerosis N/A
Completed NCT00076687 - Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function Phase 2
Completed NCT00001220 - Ultrasound and Videofluoroscopy for Diagnosing Swallowing Disorders N/A
Completed NCT03487263 - Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease Phase 1
Enrolling by invitation NCT05725759 - Rehabilitation in SOD1 ALS Treated With Tofersen
Active, not recruiting NCT03811301 - [BrainConnexion] - Neurodevice Phase I Trial N/A
Completed NCT02469896 - A Trial of Tocilizumab in ALS Subjects Phase 2
Completed NCT02011204 - Study of Electrical Impedance Myography (EIM) in ALS N/A
Completed NCT01495390 - A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers N/A
Completed NCT02870634 - Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND Phase 1
Recruiting NCT06201650 - Neurofilament Light Chain in Amyotrophic Lateral Sclerosis
Active, not recruiting NCT04240925 - Tolerability, Safety and Efficacy of Sigh Breaths During NIMV in Motor Neuron Disease N/A